NCT01301456View on ClinicalTrials.gov

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

April 30, 2012

Conditions
Diabetes MellitusDiabetes Mellitus, Type 2Glucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases
Interventions
BIOLOGICAL

Placebo

Single subcutaneous injection of placebo

BIOLOGICAL

PF-04856883

Single subcutaneous injection of PF-04856883

BIOLOGICAL

PF-04856883

Single subcutaneous injection of PF-04856883

BIOLOGICAL

PF-04856883

Single subcutaneous injection of PF-04856883

BIOLOGICAL

Placebo

Single subcutaneous injection of placebo

BIOLOGICAL

PF-04856883

Single subcutaneous injection of PF-04856883

BIOLOGICAL

PF-04856883

Single subcutaneous injection of PF-04856883

BIOLOGICAL

PF-04856883

Single subcutaneous injection of PF-04856883

BIOLOGICAL

Placebo

Multiple weekly subcutaneous injections of placebo for 3 weeks

BIOLOGICAL

PF-04856883

Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks

BIOLOGICAL

PF-04856883

Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks

BIOLOGICAL

PF-04856883

Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks

BIOLOGICAL

PF-04856883

Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks

Trial Locations (7)

19139

CRI Worldwide, LLC, Philadelphia

30308

Atlanta Center for Medical Research, Atlanta

33025

Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.), Miramar

33169

Elite Research Institute, Miami

68154

ICON Clinical Pharmacology, LLC, Omaha

78209

Healthcare Discoveries LLC d/b/a ICON Development Solutions, San Antonio

91911

Profil Institute for Clinical Research, Inc., Chula Vista

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01301456 - Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females | Biotech Hunter | Biotech Hunter